Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)

Kozlu S., ŞAHİN A. E., ÇALIŞ S., ÇAPAN Y.

PHARMAZIE, cilt.72, sa.10, ss.568-570, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 72 Sayı: 10
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1691/ph.2017.7077
  • Dergi Adı: PHARMAZIE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.568-570
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

An isocratic reversed phase HPLC method for the simultaneous determination of doxorubicine (DOX) and celecoxib (CXB) out of a nanoparticulate fixed dose combination (NanoFDC) was developed and validated. Linearity of the results was demonstrated from 1-11 mu g/mL for both components. Lower limits of detection were determined as 7 ng/mL for DOX and 13 ng/mL for CXB. Total run time was approximately 15 min.